Advertisement
Screener

Lyell Immunopharma, Inc. (LYEL) Accounts Payable

2.8 / 5 stars · 68/120 Roast Me

Lyell Immunopharma, Inc. Accounts Payable

Lyell Immunopharma, Inc. (LYEL) had Accounts Payable of $3.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Balance Sheet › Liabilities › Liabilities, Current

us-gaap:AccountsPayableCurrent · last filed 2026-08-06

  • 2026-06-30: Accounts Payable, Current $3.88M.
  • 2026-03-31: Accounts Payable, Current $5.47M.
  • 2025-12-31: Accounts Payable, Current $2.89M.
  • 2025-09-30: Accounts Payable, Current $2.57M.
Period endAccounts Payable, Current
2026-06-30$3.88M
10-Q · filed 2026-08-06
2026-03-31$5.47M
10-Q · filed 2026-05-06
2025-12-31$2.89M
10-Q · filed 2026-08-06
2025-09-30$2.57M
10-Q · filed 2025-11-12
2025-06-30$3.38M
10-Q · filed 2025-08-12
2025-03-31$3.73M
10-Q · filed 2025-05-13
2024-12-31$5.37M
10-K · filed 2026-03-12
2024-09-30$3.60M
10-Q · filed 2024-11-07
2024-06-30$4.20M
10-Q · filed 2024-08-07
2024-03-31$4.89M
10-Q · filed 2024-05-06
2023-12-31$4.82M
10-K · filed 2025-03-11
2023-09-30$4.37M
10-Q · filed 2023-11-07
2023-06-30$5.80M
10-Q · filed 2023-08-08
2023-03-31$5.73M
10-Q · filed 2023-05-04
2022-12-31$3.92M
10-K · filed 2024-02-28
2022-09-30$4.79M
10-Q · filed 2022-11-08
2022-06-30$4.25M
10-Q · filed 2022-08-04
2022-03-31$6.51M
10-Q · filed 2022-05-10
2021-12-31$3.21M
10-K · filed 2023-02-28
2021-09-30$3.53M
10-Q · filed 2021-11-12
2021-06-30$4.86M
10-Q · filed 2021-08-12
2020-12-31$9.40M
10-K · filed 2022-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55